MSD/Moderna Phase 3 Cancer Vaccine Trial Shows Improved Melanoma Survival

MSD/Merck and Moderna announced positive phase 3 results for a therapeutic cancer vaccine combined with immunotherapy in melanoma patients, improving recurrence-free survival. Detailed data are pending, and clinical trials will need to refine observations. This marks a notable advance in cancer treatment, though efficacy and broader applicability remain uncertain.